Selective Inhibitors of Toll-Like Receptor 9 (TLR9) Could Potentially Treat Fibrotic, Autoimmune, and Inflammatory Diseases.

The invention in this patent application relates to imidazopyridinyl derivatives represented herein generally by Formula 1. These compounds are inhibitors of TLR9, and may potentially be useful in treating, preventing, or slowing fibrotic diseases including nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and primary biliary cirrhosis (PBC).